Recapitulating Parkinson's disease pathology in a three-dimensional human neural cell culture model

Dis Model Mech. 2019 Apr 9;12(4):dmm038042. doi: 10.1242/dmm.038042.

Abstract

Extensive loss of dopaminergic neurons and aggregation of the protein α-synuclein into ubiquitin-positive Lewy bodies represents a major neuropathological hallmark of Parkinson's disease (PD). At present, the generation of large nuclear-associated Lewy bodies from endogenous wild-type α-synuclein, translationally regulated under its own promoter in human cell culture models, requires costly and time-consuming protocols. Here, we demonstrate that fully differentiated human SH-SY5Y neuroblastoma cells grown in three-dimensional cell culture develop Lewy-body-like pathology upon exposure to exogenous α-synuclein species. In contrast to most cell- and rodent-based PD models, which exhibit multiple diffuse α-synuclein aggregates throughout the cytoplasm, a single large nuclear inclusion that is immunopositive for α-synuclein and ubiquitin is rapidly obtained in our model. This was achieved without the need for overexpression of α-synuclein or genetic modification of the cell line. However, phosphorylation of α-synuclein within these inclusions was not observed. The system described here provides an ideal tool to screen compounds to therapeutically intervene in Lewy body formation, and to investigate the mechanisms involved in disease progression in synucleinopathies.

Keywords: 3D cell culture; Amyloid; Lewy body; Oligomer; Parkinson's; Synuclein.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers / metabolism
  • Brain-Derived Neurotrophic Factor / pharmacology
  • Cell Differentiation / drug effects
  • Cells, Cultured
  • Dopaminergic Neurons / drug effects
  • Dopaminergic Neurons / metabolism
  • Dopaminergic Neurons / pathology*
  • Humans
  • Lewy Bodies / drug effects
  • Lewy Bodies / metabolism
  • Models, Biological*
  • Parkinson Disease / pathology*
  • Phenotype
  • Protein Aggregates / drug effects
  • Tretinoin / pharmacology
  • alpha-Synuclein / metabolism

Substances

  • Biomarkers
  • Brain-Derived Neurotrophic Factor
  • Protein Aggregates
  • alpha-Synuclein
  • Tretinoin